公开(公告)号：WO2012030170A3

公开(公告)日：2012-06-28

申请号：PCT/KR2011006474

申请日：2011-08-31

Applicant: AMOREPACIFIC CORP ,  SHIN SONG SEOK ,  HONG YONG DEOG ,  BYOUN KYOUNG HEE ,  PARK MI YOUNG ,  CHOI JIN KYU ,  PARK YANG HUI ,  BAE IL HONG ,  JOO YUNG HYUP ,  LIM KYUNG MIN ,  PARK YOUNG HO

Inventor： SHIN SONG SEOK ,  HONG YONG DEOG ,  BYOUN KYOUNG HEE ,  PARK MI YOUNG ,  CHOI JIN KYU ,  PARK YANG HUI ,  BAE IL HONG ,  JOO YUNG HYUP ,  LIM KYUNG MIN ,  PARK YOUNG HO

IPC: C07D487/04 ,  A61K31/519 ,  A61P29/00 ,  C07D403/04

CPC classification number: C07D487/04 ,  A61K31/519

Abstract: Disclosed are a novel compound acting as a cannabinoid receptor-1 inhibitor, a prodrug thereof, a pharmaceutically acceptable salt thereof, and a hydrate thereof or a solvate thereof. The novel compound or the like is useful for preventing or treating diseases mediated by cannabinoid receptor-1.

Abstract translation: 公开了用作大麻素受体-1抑制剂，其前药，其药学上可接受的盐，及其水合物或其溶剂合物的新型化合物。 新型化合物等可用于预防或治疗由大麻素受体-1介导的疾病。

公开(公告)号：WO2008069500A1

公开(公告)日：2008-06-12

申请号：PCT/KR2007/006136

申请日：2007-11-30

Applicant: AMOREPACIFIC CORPORATION ,  INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY ,  CRYSTALGENOMICS, INC. ,  HONG, Yong Deog ,  KANG, Seung-hyun ,  KIM, Yeonjoon ,  BYOUN, Kyoung Hee ,  WOO, Byoung Young ,  PARK, Miyoung ,  JOO, Yung Hyup ,  KIM, Jung Ju ,  JANG, Doo Ok ,  TAE, Jinsung ,  SHIN, Dongkyu ,  KIM, Yong Eun ,  CHEON, Younghoon ,  LEE, Jae Il ,  HYUN, Young-Lan ,  RO, Seonggu ,  CHO, Joong Myung

Inventor： HONG, Yong Deog ,  KANG, Seung-hyun ,  KIM, Yeonjoon ,  BYOUN, Kyoung Hee ,  WOO, Byoung Young ,  PARK, Miyoung ,  JOO, Yung Hyup ,  KIM, Jung Ju ,  JANG, Doo Ok ,  TAE, Jinsung ,  SHIN, Dongkyu ,  KIM, Yong Eun ,  CHEON, Younghoon ,  LEE, Jae Il ,  HYUN, Young-Lan ,  RO, Seonggu ,  CHO, Joong Myung

IPC: C07D487/04

CPC classification number: C07D487/04

Abstract: The present invention relates to a novel triazolopyridazine derivative or a pharmaceutically acceptable salt thereof, and an Acetyl-CoA Carboxylase2 (ACC2) comprising same as an active ingredient. The triazolopyridazine derivative of the present invention effectively inhibits the activity of ACC2 and it may be used for preventing or treating obesity, diabetes, dyslipidemia and diseases related to metabolic syndrome.

Abstract translation: 本发明涉及一种新的三唑并哒嗪衍生物或其药学上可接受的盐，以及含有作为活性成分的乙酰辅酶A羧化酶2（ACC2）。 本发明的三唑并哒嗪衍生物有效抑制ACC2的活性，可用于预防或治疗肥胖症，糖尿病，血脂异常和与代谢综合征有关的疾病。